多囊卵巢综合征早期妊娠炎症与代谢调节生物标志物研究
发现PCOS孕妇MCP1和FABP4浓度分别高15%和32%,但校正BMI后关联减弱,且这些标志物未改变PCOS与母婴结局的关联。
要点
- PCOS孕妇早孕期MCP1高15%,FABP4高32%,但校正BMI后关联减弱。
- MCP1和FABP4与母婴结局无交互作用。
- PCOS相关炎症标志物升高很大程度上反映母体肥胖。
核心结论
- PCOS孕妇早孕期MCP1和FABP4浓度升高,主要反映母体肥胖。
- 这些标志物未改变PCOS与妊娠结局的关联。
研究设计与样本
- 横断面研究,采用交互分析,汇总两项国际多中心临床试验的基线数据。
主要发现
- 其他生物标志物在PCOS组与无PCOS组间无差异。
- MCP1或FABP4与母婴结局无交互作用。
临床怎么用
- 早孕期PCOS孕妇的MCP1和FABP4升高可能反映肥胖而非独立PCOS效应。
- 这些标志物目前不用于预测PCOS孕妇的不良妊娠结局。
局限性
- 横断面设计无法推断因果。
- 样本量有限,需更大规模纵向研究验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To profile biomarkers of inflammation and metabolic regulation in early pregnancy among women with and without polycystic ovary syndrome (PCOS), and to assess whether these biomarkers influence the relationship between PCOS and adverse maternal or neonatal outcomes. DESIGN: Cross-sectional study with interaction analyses using pooled baseline data from 2 international multicenter clinical trials. SUBJECTS: One hundred and fifty-one pregnant women (at <24 weeks' gestation) at risk of gestational diabetes mellitus, including 65 with PCOS and 86 without PCOS. MAIN OUTCOME MEASURES: Early pregnancy markers of inflammation and metabolic regulation were assessed, including C-reactive protein, tumor necrosis factor-α, interleukins, monocyte chemoattractant protein-1 (MCP1), fatty acid binding protein-4 (FABP4), growth differentiation factor-15, and adipokines (total adiponectin, leptin, resistin, chemerin, vaspin, and cathepsin-S). Biomarkers differing by PCOS status were further examined for interaction effects on maternal and neonatal outcomes. RESULTS: Monocyte chemoattractant protein-1 concentrations were 15% higher in women with PCOS compared with those without (geometric mean ratio [GMR]: 1.15; 95% CI: 1.01, 1.31; P & .04), but this association was attenuated after adjustment for maternal age and body mass index (BMI). Early pregnancy FABP4 concentrations were 32% higher in women with PCOS compared with those without (GMR: 1.32; 95% CI: 1.04, 1.68; P & .02), and this association remained significant after adjustment for maternal age (GMR: 1.34; 95% CI: 1.05-1.71; P & .02), but was attenuated after adjustment for BMI. No other biomarkers differed by PCOS status, and MCP1 or FABP4 showed no interactions with maternal or neonatal outcomes. CONCLUSION: Monocyte chemoattractant protein-1 and FABP4 concentrations were elevated in early pregnancy among women with PCOS, largely reflecting maternal adiposity. These markers did not modify associations between PCOS and pregnancy outcomes. Larger longitudinal studies are needed to clarify underlying inflammatory and metabolic pathways.
引用
- Alesi S, Mason T, Ellery SJ, et al. Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome. J Clin Endocrinol Metab. 2026. PMID: 41802911. doi:10.1210/clinem/dgag098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。